Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CR-101-2
- Development stage
- Unknown
- Lead developer
- Currax Pharmaceuticals
01
Overview
CR-101-2 is an investigational pharmaceutical candidate currently in Phase 1 clinical development by Currax Pharmaceuticals for the treatment of obesity. It is part of a suite of pipeline assets aimed at expanding Currax's portfolio in the metabolic disease space. CR-101-2 is specifically characterized as a once-a-day formulation, a dosing regimen designed to potentially improve patient adherence and therapeutic outcomes compared to more frequent dosing schedules. However, as of the current reporting, the specific active pharmaceutical ingredients, molecular targets, and drug modality have not been publicly disclosed by the developer.
Beyond the preview
Go deeper on CR-101-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CR-101-2.